Literature DB >> 15020080

Identification and functional characterization of a highly polymorphic region in the human TRAIL promoter in multiple sclerosis.

Alexandra Weber1, Klaus-Peter Wandinger, Wolf Mueller, Orhan Aktas, Oliver Wengert, Eva Grundström, Stefan Ehrlich, Christine Windemuth, Tanja Kuhlmann, Thomas Wienker, Wolfgang Brück, Frauke Zipp.   

Abstract

TNF-related apoptosis-inducing ligand (TRAIL) is not only involved in cell death but also in other immunoregulatory mechanisms. So far, the regulation of the TRAIL pathway in physiologic and pathologic conditions remains unclear. Due to the implication in brain damage and the elevated expression in peripheral immune cells of patients with multiple sclerosis (MS), an autoimmune disease of the central nervous system, TRAIL might play a central role in the pathology of this disease. Here, we have identified a highly polymorphic region in the TRAIL promoter. Using single-strand conformation polymorphism analysis, we found four single nucleotide polymorphisms (SNPs) within 111 base pairs. One of these SNPs is located in a binding site for the transcription factor AP-1. However, the RNA and protein expression of TRAIL revealed no obvious differences in relation to the genotypes. Furthermore, investigating samples from both MS patients and healthy controls we could not detect any association of these newly described polymorphisms to the clinical disease pattern. Thus, the TRAIL promoter contains a highly polymorphic area which has, however, no impact on molecule expression, and is neither directly related to increased risk of developing MS nor associated with a certain course of this heterogeneous disease in our population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15020080     DOI: 10.1016/j.jneuroim.2003.12.014

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  12 in total

1.  Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals.

Authors:  Stacey A Rizza; Nathan W Cummins; David N Rider; Sahar Saeed; Marina B Klein; Andrew D Badley
Journal:  AIDS       Date:  2010-11-13       Impact factor: 4.177

2.  sTRAIL levels and TRAIL gene polymorphisms in Chinese patients with fatty liver disease.

Authors:  Xiaohua Yan; Liyun Xu; Jianni Qi; Xiaohong Liang; Chunhong Ma; Chun Guo; Lining Zhang; Wensheng Sun; Jiyun Zhang; Xiaoyi Wei; Lifen Gao
Journal:  Immunogenetics       Date:  2009-07-23       Impact factor: 2.846

3.  Tumor necrosis factor-related apoptosis inducing ligand gene polymorphisms are correlated with gastric cancer in central China.

Authors:  Changgao Wang; Shufang Xu; Fengming Yi; Xiaobing Wang; Yuan Lei; Sha Huang; Rui Zhou; Bing Xia
Journal:  Pharm Res       Date:  2013-11-26       Impact factor: 4.200

Review 4.  Regulation of the human TRAIL gene.

Authors:  Joshua E Allen; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2012-08-15       Impact factor: 4.742

5.  TRAIL/TRAIL receptor system and susceptibility to multiple sclerosis.

Authors:  Carlos López-Gómez; Oscar Fernández; Juan Antonio García-León; María Jesús Pinto-Medel; Begoña Oliver-Martos; Jesús Ortega-Pinazo; Margarita Suardíaz; Lucía García-Trujillo; Cristina Guijarro-Castro; Julián Benito-León; Isidro Prat; Jezabel Varadé; Roberto Álvarez-Lafuente; Elena Urcelay; Laura Leyva
Journal:  PLoS One       Date:  2011-07-21       Impact factor: 3.240

6.  Polymorphisms in Toll-like receptors 2, 4, and 9 are highly associated with hearing loss in survivors of bacterial meningitis.

Authors:  Gijs Th J van Well; Marieke S Sanders; Sander Ouburg; A Marceline van Furth; Servaas A Morré
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

7.  Is there any correlation between TNF-related apoptosis-inducing ligand (TRAIL) genetic variants and breast cancer?

Authors:  Yemliha Yildiz; Ilhan Yaylim-Eraltan; Soykan Arikan; H Arzu Ergen; Seden Küçücük; Turgay Isbir
Journal:  Arch Med Sci       Date:  2010-12-29       Impact factor: 3.318

Review 8.  Clinical perspectives of TRAIL: insights into central nervous system disorders.

Authors:  Veronica Tisato; Arianna Gonelli; Rebecca Voltan; Paola Secchiero; Giorgio Zauli
Journal:  Cell Mol Life Sci       Date:  2016-02-24       Impact factor: 9.261

9.  TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response.

Authors:  Carlos López-Gómez; Begoña Oliver-Martos; María-Jesús Pinto-Medel; Margarita Suardiaz; Virginia Reyes-Garrido; Patricia Urbaneja; Óscar Fernández; Laura Leyva
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-03-03       Impact factor: 10.154

10.  Mining gene expression data of multiple sclerosis.

Authors:  Pi Guo; Qin Zhang; Zhenli Zhu; Zhengliang Huang; Ke Li
Journal:  PLoS One       Date:  2014-06-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.